

The Medical Letter[®]

on Drugs and Therapeutics

Volume 68

February 2, 2026

ISSUE No.
1747

IN THIS ISSUE

In Brief: New Warning for Injectable Medroxyprogesterone..... p 24

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions, Site Licenses, Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter[®]

on Drugs and Therapeutics

Volume 68 (Issue 1747)

February 2, 2026

Take CME Exams

IN BRIEF

New Warning for Injectable Medroxyprogesterone

The FDA now requires that product labels for the long-acting injectable progestin contraceptive medroxyprogesterone acetate (MPA; *Depo-Provera CI*, and generics; *Depo-SubQ Provera 104*) include a warning about the risk of meningioma associated with its use.

The new warning was based on observational studies that found an association between MPA use and meningioma. In one case-control analysis that included 18,061 women who had intracranial surgery for a meningioma over a period of 9 years and 90,305 controls, a significantly greater percentage of patients in the case group had been exposed to injectable MPA for >1 year (0.04% vs 0.01%).^{1,2} In a retrospective cohort study in >10 million women, use of injectable MPA for >4 years or in those ≥31 years old was associated with a significantly greater risk of meningioma compared to controls (7.39 vs 3.05 cases per 100,000 patient-years; relative risk 2.43 [95% CI 1.77-3.33]). Oral MPA was also associated with an increased risk of meningioma, but to a lesser degree.³

The updated labels recommend monitoring for signs and symptoms of meningioma and stopping the drug if a meningioma is detected. ■

1. N Roland et al. Use of progestogens and the risk of intracranial meningioma: national case-control study. *BMJ* 2024; 384:e078078.
2. ACOG. Counseling patients on birth control injection and meningioma: a guide to patient-centered, evidence-based conversations. Available at: <https://bit.ly/4jogIX0>. Accessed January 9, 2026.
3. T Xiao et al. Depot medroxyprogesterone acetate and risk of meningioma in the US. *JAMA Neurology* 2025; 82:1094.

PRESIDENT, EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **EDITOR IN CHIEF EMERITUS:** Mark Abramowicz, M.D.; **VICE PRESIDENT, ADMINISTRATION:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Dartmouth Hitchcock Medical Center; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
2 Madison Ave, Ste 211
Larchmont, NY 10538
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year – \$179; \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints – \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:     

Copyright 2026. ISSN 1523-2859

The
Medical
Letter